Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Active, not recruiting2
Not yet recruiting1
Completed1
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

active_not_recruiting233%
not_yet_recruiting117%
completed117%
suspended117%
terminated117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_2

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

NCT05605496
suspendedphase_1

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

NCT05546879
completedphase_1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT05546853
not_yet_recruitingphase_1

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

NCT06203821
terminatedphase_1

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

NCT06150040
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05605496Phase 2

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Active Not Recruiting
NCT05546879Phase 1

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

Suspended
NCT05546853Phase 1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Completed
NCT06203821Phase 1

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Not Yet Recruiting
NCT06150040Phase 1

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

Terminated
NCT04652076Phase 1

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active Not Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6